Please assess the completion status of the following clinical trial:

Trial Title: Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients between the ages of 18 and 75 years undergoing non-urgent, elective spinal fusion at Massachusetts General Hospital who are admitted to the neurosurgery floor from the operating room~Exclusion Criteria:~* Patients who are taken to the operating room from another inpatient floor or service (already hospitalized prior to surgery)~* Patients with evidence of bowel obstruction~* Patients unable to take oral medications by mouth or by enteric feeding tube (gastrostomy or jejunostomy)~* Patients with a documented or potential allergy or adverse reaction to Movantik (naloxegol) from outpatient use~* Patients currently taking Movantik (naloxegol) in the outpatient setting~* Patients with a preoperative diagnosis of irritable bowel syndrome (IBS) obtained via Rome III questionnaire on screening~* Patients with disruptions to the blood-brain barrier (eg, multiple sclerosis, recent brain injury, Alzheimer's disease, and uncontrolled epilepsy)~* Patients with a history of cancer.~* Patients concomitantly using strong CYP3A4 inhibitors (eg, clarithromycin, ketoconazole), strong CYP3A4 inducers and other opioid antagonists.~* Patients with severe hepatic impairment.~* Patients with a previous history of or risk of bowel perforation.~* Patients with a post-op regional anesthetic technique employed like a continuous epidural or spinal.~* Patients for which local anesthetics will be placed in the wound.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MOVANTIK™ (naloxegol) (Type: EXPERIMENTAL): Subjects in the treatment group will be administered MOVANTIK™ (naloxegol) 25 mg tablet or placebo once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing). Subjects with renal impairments (creatine clearance rate of less than 60 mL/min) will receive a 12.5 mg dose tablet of naloxegol in place of the 25 mg dose as advised by FDA guidelines. For patients who are unable to swallow the tablet whole, the tablet can be crushed and given orally or administered via nasogastric tube.
- Sugar pill (Type: PLACEBO_COMPARATOR): Matching placebo consists of an inert mixture supplied by AstraZeneca in identical-appearing tablets. Subjects in the placebo group will be administered a placebo tablet once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing).

Based on this trial design, predict the completion outcome and termination type (if applicable).